Epitalon

Intriguing in-vitro telomerase activation data and rodent lifespan studies, but human evidence is extremely limited and confined to Russian publications.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Khavinson group publications report telomerase activation in human cell cultures and lifespan extension in rodents. No international replication or large human trials.

• In-vitro telomerase activation demonstrated
• Rodent lifespan extension reported by one group
• Minimal reported side effects in available literature

Community protocols: 5–10 mg subcutaneously daily for 10–20 day cycles. No validated dosing.

• Injection-site reactions
• Theoretical oncogenic risk from telomerase activation

Not approved in any Western country. Telomerase activation carries theoretical oncogenic risk.

All significant data come from a single research group. Telomerase activation in a dish does not equate to anti-aging in humans.

• Longevity30
• Sleep15